Predictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: Results from the TREAT Asia HIV Observational Database

Journal of the International Association of Providers of AIDS Care

Volumn 12, Issue 4, 2013, Pages 270-277

  Byakwaga, H ^a   Petoumenos, K ^a   Ananworanich, J ^b   Zhang, F ^c   Boyd, M A ^a   Sirisanthana, T ^d   Li, P C K ^e   Lee, C ^f   Mean, C V ^g   Saphonn, V ^g   Omar, S F S ^h   Pujari, S ⁱ   Phanuphak, P ^b   Lim, P L ^j   Kumarasamy, N ^k   Chen, Y M A ^l   Merati, T P ^m   Sungkanuparph, S ⁿ   Ditangco, R ^o   Oka, S ^p   Tau, G ^q   Zhou, J ^a   Law, M G ^a   Emery, S ^a   more..

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d Research Institute for Health Sciences   (Thailand)

^e QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^f HOSPITAL SUNGAI BULOH   (Malaysia)

^g Dermatology and STD   (Cambodia)

^h UNIVERSITY OF MALAYA   (Malaysia)

ⁱ Institute of Infectious Diseases   (India)

^j TAN TOCK SENG HOSPITAL   (Singapore)

^k YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^l NATIONAL YANG MING UNIVERSITY   (Taiwan)

^m UDAYANA UNIVERSITY   (Indonesia)

ⁿ MAHIDOL UNIVERSITY   (Thailand)

^o RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^p NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^q PORT MORESBY GENERAL HOSPITAL   (Papua New Guinea)

more..

Author keywords

antiretroviral therapy; disease progression; HIV; resource limited settings

Indexed keywords

HEMOGLOBIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; ASIA; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; DISEASE TRANSMISSION; ETHNICITY; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HERPES SIMPLEX; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SURVIVAL; TREATMENT DURATION; TUBERCULOSIS;

ANTIRETROVIRAL THERAPY; DISEASE PROGRESSION; HIV; RESOURCE-LIMITED SETTINGS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-RETROVIRAL AGENTS; ASIA; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DATABASES, FACTUAL; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ETHNIC GROUPS; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HIV INFECTIONS; HIV-1; HUMANS; MALE; SUBSTANCE ABUSE, INTRAVENOUS; SURVIVAL ANALYSIS;

EID: 84880437582     PISSN: 23259574     EISSN: 23259582     Source Type: Journal    
DOI: 10.1177/1545109712469684     Document Type: Article

References (45)

1. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ.. 1997 ; 315 (7117). 1194-1199
2. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002 ; 360 (9327). 119-129
3. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet.. 1998 ; 352 (9142). 1725-1730
4. Sterne JA, Hernan MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005 ; 366 (9483). 378-384
5. Towards Universal Access: scaling up priority HIV/AIDS interventions in the health sector. Progress Report 2009. http://www.who.int/hiv/pub/tuapr-2009- en.pdf
6. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006 ; 367 (9513). 817-824
7. Nash D, Katyal M, Brinkhof MW, et al. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS. 2008 ; 22 (17). 2291-2302
8. Ivers LC, Kendrick D, Doucette K, et al. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis. 2005 ; 41 (2). 217-224
9. Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med. 2000 ; 133 (6). 401-410
10. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997 ; 126 (12). 946-954
11. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS. 2004 ; 18 (1). 51-58
12. Volberding PA, Lagakos SW, Grimes JM, et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med. 1995 ; 333 (7). 401-407
13. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://www.aidsinfo.nih.gov/guidelines/. Accessed January 13, 2011.
14. Zhou J, Kumarasamy N, Ditangco R, et al. The treat Asia HIV observational database: baseline and retrospective data. J Acquir Immune Defic Syndr. 2005 ; 38 (2). 174-179
15. Morb Mortal Wkly Rep. 1992 ; 41: 1-19
16. Lane HC, Masur H, Gelmann EP, et al. Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. Am J Med. 1985 ; 78 (3). 417-422
17. Bonnet F, Thiébaut R, Chêne G, et al. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France. HIV Med. 2005 ; 6 (3). 198-205
18. World Health Organisation. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 Revision. http://whqlibdoc.who.int/publications/2010/9789241599764-eng.pdf
19. Kaufmann G, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med. 2003 ; 163 (18). 2187-2195
20. Smith C, Sabin C, Lampe F, et al. The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. AIDS. 2003 ; 17 (7). 963-969
21. Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet. 2000 ; 356 (9226). 291-296
22. Lundgren JD, Mocroft A, Gatell JM, et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis. 2002 ; 185 (2). 178-187
23. Chene G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet. 2003 ; 362 (9385). 679-686
24. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients. J Acquir Immune Defic Syndr. 2007 ; 46 (5). 607-615
25. Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion: incidence and predictors. AIDS. 2004 ; 18 (4). 673-681
26. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA. 1999 ; 282 (23). 2220-2226
27. Ledergerber B, Mocroft A, Reiss P, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med. 2001 ; 344 (3). 168-174
28. Duncombe C, Kerr SJ, Ruxrungtham K, et al. HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting. AIDS. 2005 ; 19 (2). 169-178
29. Mocroft A, Kirk O, Barton SE, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS.. 1999 ; 13 (8). 943-950
30. Anastos K, Shi Q, French AL, et al. Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2004 ; 35 (4). 383-392
31. Costello C, Nelson KE, Suriyanon V, et al. HIV-1 subtype E progression among northern Thai couples: traditional and non-traditional predictors of survival. Int J Epidemiol. 2005 ; 34 (3). 577-584
32. Kowalska JD, Mocroft A, Blaxhult A, et al. Current hemoglobin levels are more predictive of disease progression than hemoglobin measured at baseline in patients receiving antiretroviral treatment for HIV type 1 infection. AIDS Res Hum Retroviruses. 2007 ; 23 (10). 1183-1188
33. Zhou J, Kumarasamy N. Predicting short-term disease progression among HIV-infected patients in Asia and the Pacific region: preliminary results from the TREAT Asia HIV Observational Database (TAHOD). HIV Med. 2005 ; 6 (3). 216-223
34. Srasuebkul P, Lim PL, Lee MP, et al. Short-term clinical disease progression in HIV-infected patients receiving combination antiretroviral therapy: results from the TREAT Asia HIV observational database. Clin Infect Dis. 2009 ; 48 (7). 940-950
35. Maas JJ, Dukers N, Krol A, et al. Body mass index course in asymptomatic HIV-infected homosexual men and the predictive value of a decrease of body mass index for progression to AIDS. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 ; 19 (3). 254-259
36. Mekonnen Y, Dukers NH, Sanders E, et al. Simple markers for initiating antiretroviral therapy among HIV-infected Ethiopians. AIDS. 2003 ; 17 (6). 815-819
37. Badri M, Wood R. Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings. AIDS. 2003 ; 17 (4). 541-545
38. Eskild A, Magnus P, Samuelsen SO, Sohlberg C, Kittelsen P. Differences in mortality rates and causes of death between HIV positive and HIV negative intravenous drug users. Int J Epidemiol. 1993 ; 22 (2). 315-320
39. Selwyn PA, Hartel D, Wasserman W, Drucker E.. Impact of the AIDS epidemic on morbidity and mortality among intravenous drug users in a New York City methadone maintenance program. Am J Public Health. 79 (10). 1358-1362
40. Zhou J, Elliott J, Li PC, et al. Risk and prognostic significance of tuberculosis in patients from The TREAT Asia HIV Observational Database. BMC Infect Dis. 2009 ; 9 ( 46 ):
41. Kumarasamy N, Solomon S, Flanigan TP, Hemalatha R, Thyagarajan SP, Mayer KH. Natural history of human immunodeficiency virus disease in southern India. Clin Infect Dis. 2003 ; 36 (1). 79-85
42. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R.. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS. 2005 ; 19 (18). 2141-2148
43. Etard JF, Ndiaye I, Thierry-Mieg M, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS. 2006 ; 20 (8). 1181-1189
44. Lortholary O, Fontanet A, Mémain N, Martin A, Sitbon K, Dromer F. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS. 2005 ; 19 (10). 1043-1049
45. French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med. 2000 ; 1 (2). 107-115